NeuralPulse develops implantable neuromodulation systems designed to detect and respond to pathological brain activity in real time. The company’s platform focuses on adaptive stimulation that can both probe neural responses and intervene when abnormal patterns are detected. Its approach emphasizes continuous monitoring and closed-loop control to prevent neurological events. NeuralPulse positions its technology within regulated clinical development pathways.

The technology records neural signals to identify biomarkers associated with seizure onset or heightened seizure risk. By analyzing these signals, the system predicts imminent events and delivers responsive electrical stimulation to disrupt pathological activity. This adaptive, closed-loop framework enables intervention tailored to individual neural dynamics rather than fixed stimulation schedules. The implant is designed for chronic use, supporting long-term seizure management.

NeuralPulse targets epilepsy and related seizure disorders where early detection and timely intervention can improve outcomes. The platform is intended for use in specialized clinical settings under professional supervision. Its focus reflects broader movement toward responsive neuromodulation therapies that adapt in real time to a patient’s brain activity.